entertainment -WSS

entertainment

author：hotspot 2025-09-27 10:05:53 - browse：2912

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

WSS

New brain studies show LSD's effects on the brain in full color

New brain studies show LSD's effects on the brain in full color

Medicare Advantage today, explained in one chart

When waiting feels immoral: Empathy in the emergency department

Why doctors need education on FDA device approval process

Elizabeth Holmes banned from government health programs

leisure time

entertainment

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Alkermes shareholders re

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

When waiting feels immoral: Empathy in the emergency department

In Memoriam: Notable people who died in 2023

Physicians aren't 'burning out.' They're suffering from moral injury

As demand for Covid shots wanes, Moderna seeks its next success

Study links childhood stress with decline in older age

focus

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

The cancer stories no one wants to hear

Group behind ProMed defends move to subscription

How to ethically and practically extend health care to all

The cancer stories no one wants to hear

A controversial new treatment promises to make little people taller

focus

hotspot

entertainment

focus